NCT01908556View on ClinicalTrials.gov

Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)

PHASE4UnknownINTERVENTIONAL

Enrollment

3,545

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2015

Conditions

is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.

Interventions

DRUG

Letrozole

Trial Locations (1)

91054

Frauenklinik University Hospital, Erlangen

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

collaborator

ClinSol

UNKNOWN

lead

Institut fuer Frauengesundheit

OTHER

NCT01908556 - Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) | Biotech Hunter | Biotech Hunter